Cosmos Health Inc.
- Open
- 0.24
- Day high
- 0.26
- Day low
- 0.23
- Prev close
- 0.22
- Volume
- 5.3M
- Mkt cap
- $24M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.2
- P/S
- 0.3
- Yield
- —
- Per share
- —
- ▲Insiders net buying $457K over the last 3 months (5 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions reducing (13F)
Cosmos Health Inc. (COSM) is a Healthcare company listed on NASDAQ. The stock is down 69% over the past year. Over the trailing 3 months, insiders filed 5 open-market buys and 0 sales (SEC Form 4).
Cosmos Health Inc. (COSM) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
COSM earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 19, 2026 | $-0.10 | $-0.10 | +0.0% | $19M | +1.7% |
| May 21, 2026 | $-0.06 | $-0.06 | +0.0% | $18M | +0.0% |
| Nov 14, 2025 | $-0.01 | $-0.17 | -1600.0% | $17M | +4.3% |
| Aug 18, 2025 | $0.01 | $-0.06 | -700.0% | $15M | -15.6% |
| May 15, 2025 | $-0.03 | $0.01 | +133.3% | $14M | -11.5% |
| Nov 14, 2024 | $-0.11 | $-0.45 | -309.1% | $12M | -14.4% |
| Aug 20, 2024 | $-0.14 | $-0.04 | +71.4% | $13M | -9.2% |
| Nov 21, 2023 | — | $-0.09 | — | $13M | — |
| Aug 15, 2023 | — | $0.02 | — | $12M | — |
| May 16, 2023 | — | $-0.04 | — | $12M | — |
| Mar 6, 2023 | — | $-2.15 | — | $16M | — |
| Nov 14, 2022 | — | $-2.00 | — | $12M | — |
COSM insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 31, 2026 | Siokas Grigoriosdirector, 10 percent owner, officer: Chief Executive Officer | Buy | 349,825 | $0.20 |
| Jul 30, 2026 | Siokas Grigoriosdirector, 10 percent owner, officer: Chief Executive Officer | Buy | 766,284 | $0.18 |
| Jul 30, 2026 | Terzis Georgiosofficer: Chief Financial Officer | Grant | 328,407 | $0.18 |
| Jun 17, 2026 | Terzis Georgiosofficer: Chief Financial Officer | Buy | 168,135 | $0.25 |
| Jun 12, 2026 | Siokas Grigoriosdirector, 10 percent owner, officer: Chief Executive Officer | Buy | 701,447 | $0.23 |
| Jun 12, 2026 | Siokas Grigoriosdirector, 10 percent owner, officer: Chief Executive Officer | Buy | 218,447 | $0.21 |
| Jun 11, 2026 | Demetriades Demetrios G.director, officer: Secretary | Grant | 20,000 | $0.28 |
| Jun 11, 2026 | Hoidas John Jamesdirector | Grant | 20,000 | $0.28 |
| Jun 11, 2026 | Karkantzos Theodoros Christosdirector | Grant | 20,000 | $0.28 |
| Jun 11, 2026 | Aslidis Anastasiosdirector | Grant | 40,000 | $0.28 |
| Jun 11, 2026 | Bhutawala Suheldirector | Grant | 20,000 | $0.28 |
| Jun 11, 2026 | Terzis Georgiosofficer: Chief Financial Officer | Grant | 850,000 | $0.28 |
| Jun 11, 2026 | Siokas Grigoriosdirector, 10 percent owner, officer: Chief Executive Officer | Grant | 2,350,000 | $0.28 |
| Feb 13, 2026 | Siokas Grigoriosdirector, 10 percent owner, officer: Chief Executive Officer | Buy | 388,532 | $0.37 |
| Feb 12, 2026 | Siokas Grigoriosdirector, 10 percent owner, officer: Chief Executive Officer | Buy | 291,262 | $0.41 |
Source: COSM SEC Form 4 filings, latest Jul 31, 2026. For informational purposes only — not investment advice.
See the full COSM insider & 13F page →Cosmos Health Inc. company profile
Overview
Cosmos Health Inc. (NASDAQ:COSM) is a vertically integrated pharmaceutical company founded in 2009 and headquartered in Chicago, Illinois. The company went public in July 2010 and operates as a specialty pharmaceutical manufacturer and distributor with a focus on branded and generic pharmaceuticals, nutraceuticals, and medical devices. Cosmos Health has established distribution operations across multiple countries, with key facilities in Greece and the United Kingdom, serving wholesale pharmaceutical distributors and independent retail pharmacies through both traditional distribution channels and e-commerce platforms.
Business
Cosmos Health operates in the specialty and generic pharmaceutical manufacturing and distribution industry, which involves the production, procurement, and distribution of medications and health-related products to healthcare providers and consumers. The pharmaceutical distribution industry serves as a critical intermediary between drug manufacturers and end-users, ensuring that medications reach patients through pharmacies, hospitals, and other healthcare facilities. The company's core business revolves around a vertically integrated model that combines manufacturing, distribution, and retail operations. This integration allows Cosmos Health to control multiple stages of the pharmaceutical supply chain, from product development and manufacturing to final distribution to customers. Cosmos Health's product portfolio includes several key segments: 1. Branded and Generic Pharmaceuticals - The company develops, manufactures, and distributes both proprietary branded medications and generic equivalents of existing drugs. Generic pharmaceuticals are bioequivalent versions of brand-name drugs that can be sold once the original patent expires, typically at lower prices. 2. Nutraceuticals - These are products that combine nutritional and pharmaceutical benefits, including dietary supplements, vitamins, and functional foods that provide health benefits beyond basic nutrition. 3. Over-the-Counter (OTC) Medications - These are medications that can be purchased without a prescription, including pain relievers, cold medicines, and other common health products. 4. Healthcare and Baby Products - This segment includes various health and wellness products, as well as specialized products for infant care. 5. Medical Devices - The company also distributes various medical devices and equipment used in healthcare settings. The company operates through multiple distribution channels, including traditional wholesale distribution to pharmacies and healthcare providers, as well as an e-commerce marketplace that allows direct-to-consumer sales and broader market reach.
Competitive moat
Cosmos Health operates in a highly competitive pharmaceutical distribution industry with limited sustainable competitive advantages. The company's primary potential moat lies in its vertical integration strategy, which theoretically allows it to capture value at multiple points in the pharmaceutical supply chain. By combining manufacturing, distribution, and retail operations, the company can potentially achieve better margins and more direct customer relationships than pure-play distributors. However, this moat appears to be relatively weak for several reasons. The pharmaceutical distribution industry is characterized by intense competition from much larger, well-established players with significant scale advantages. Major pharmaceutical distributors like McKesson, AmerisourceBergen, and Cardinal Health dominate the market with vast distribution networks, substantial purchasing power, and long-established relationships with both suppliers and customers. The company's regulatory approvals and licenses provide some barrier to entry, as pharmaceutical distribution requires compliance with strict regulatory requirements. However, these same regulations also create ongoing compliance costs that can be particularly burdensome for smaller players. Competitive threats come from multiple directions. Large pharmaceutical distributors can leverage their scale to offer lower prices and better service levels. Direct-to-pharmacy sales by pharmaceutical manufacturers can bypass distributors entirely. The growth of pharmacy chains and hospital systems with their own distribution capabilities reduces the addressable market for independent distributors. Additionally, the rise of digital health platforms and direct-to-consumer pharmaceutical sales creates new competitive dynamics. The company's geographic diversification across the US, Greece, and UK provides some protection against localized market pressures, but this advantage is limited by the company's relatively small scale in each market. The e-commerce platform offers some differentiation, but e-commerce capabilities are increasingly table stakes rather than competitive advantages in the pharmaceutical industry. Overall, Cosmos Health appears to lack a strong, defensible moat and faces significant competitive pressures from larger, better-capitalized competitors in a mature industry with limited growth prospects.
Risks & safety
Cosmos Health presents significant financial risks with a very narrow margin of safety based on its current financial position. • Cash Position and Burn: The company has extremely low cash reserves of $742,881 as of Q1 2025, down from $3.3 million in Q3 2024. With negative operating cash flows of $7.7 million in FY 2024 and continuing losses, the company faces immediate liquidity concerns. • Debt and Solvency: Current ratio of 1.05 indicates the company can barely meet short-term obligations. Total current liabilities of $26.6 million nearly match current assets of $27.8 million. Debt-to-equity ratio of 0.21 is manageable, but the company's negative equity position raises solvency concerns. • Valuation Metrics: Trading at 0.44x book value suggests potential undervaluation, but negative earnings make traditional P/E ratios meaningless. EV/EBITDA is negative due to negative EBITDA, indicating operational losses. • Operational Performance: Consistent negative net income ($16.2 million loss in FY 2024) and negative EBITDA ($13.9 million in FY 2024) demonstrate the company's inability to generate profits from operations. • Working Capital: The company's working capital position is precarious, with inventory and receivables tying up significant capital while generating negative returns. The margin of safety is extremely thin to non-existent, with immediate concerns about the company's ability to continue operations without additional financing.
Recent development
Based on the available financial data, Cosmos Health has been navigating significant operational challenges over the past few years. The company has maintained relatively stable revenue levels, generating approximately $50-54 million annually from FY 2022 through FY 2024, indicating some consistency in its core distribution business despite market pressures. However, the company has struggled with profitability and cash management. Net losses have been substantial and persistent, with losses of $13.8 million in FY 2022, $18.5 million in FY 2023, and $16.2 million in FY 2024. This pattern suggests ongoing operational inefficiencies or market pressures that the company has been unable to address effectively. The company's cash position has deteriorated dramatically, falling from over $20 million in FY 2022 to just $315,105 by the end of FY 2024, and further declining to $742,881 in Q1 2025. This cash burn indicates either significant operational losses, capital expenditures, or debt service requirements that have strained the company's liquidity. Working capital management has become increasingly challenging, with the current ratio declining from 2.58 in FY 2022 to 0.99 in FY 2024, suggesting the company is struggling to maintain adequate liquidity to meet short-term obligations. The company appears to have been focusing on maintaining its international operations across Greece and the UK while continuing to develop its e-commerce platform capabilities. However, without detailed earnings call transcripts, specific strategic initiatives and management commentary on future direction are not available from the provided data. The financial trajectory suggests the company may be in a period of financial distress, potentially requiring additional financing, operational restructuring, or strategic alternatives to ensure continued viability.
COSM company profile · for informational purposes only — not investment advice.
Track COSM with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free